Jim Cramer Says “I Should Have Pulled the Trigger on Regeneron”

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the stocks Jim Cramer looked at. When a caller inquired about the stock, Cramer said:

Oh man, you know what? I should have pulled the trigger on Regeneron when I sat down with them at the JPMorgan conference. I realized that the Charitable Trust should have owned it. It would’ve a much better, really much better drug stock than the others that we have, with the exception of Eli Lilly.

Stock market data. Photo by Photo by Alesia Kozik

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) sells medicines for eye conditions, immune disorders, cancer, cardiovascular issues, infections, and rare diseases. During the December 1, 2025, episode, a caller highlighted that the stock is up significantly from its summer 2025 lows and asked Cramer if it can continue its momentum. In response, the Mad Money host stated:

Yes, down 30 today… Well, it’s a $750 stock. Now, let me just tell you something. Regeneron’s move has been quiet, but Len Schleifer has been telling me, stay focused on what they’re doing. They’re doing a lot of good stuff. I lost sight of it. I shouldn’t have. This one and Amgen bother me. They happened without me, and that was my bad, and I’m glad you brought it to our attention.

While we acknowledge the risk and potential of REGN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than REGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.  Follow Insider Monkey on Google News.